文献速递白血病

儿童急性淋巴细胞白血病高危超二倍体低危亚型的定义:UKALL97/99与UKALL2003试验回顾性分析

Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials.
PubMed 文献 · Lancet Haematol · 2021-01-01

该回顾性分析利用UKALL97/99(n=456)和UKALL2003(n=725)两个连续试验的发现与验证队列,评估高危超二倍体儿童急性淋巴细胞白血病的预后风险因素。研究发现四条染色体的三体状态提供最佳预后信息,良好风险核型为+17和+18或+17或+18且无+5和+20。

要点

  • 高危超二倍体良好风险核型:+17和+18或+17或+18且无+5和+20。
  • 验证队列中良好风险组10年复发率5% vs 16%,无事件生存率92% vs 81%。
  • 该预后特征独立于微小残留病,且优于其他高危超二倍体风险特征。

核心结论

  • UKALL高危超二倍体特征可定义低危亚型,未来风险分层应考虑修改定义。

研究设计与样本

  • 回顾性分析,发现队列UKALL97/99(n=456)和验证队列UKALL2003(n=725)。
  • UKALL97/99招募1997年1月1日至2002年6月15日年龄1-18岁患者,UKALL2003招募2003年10月1日至2001年6月30日年龄1-24岁患者。
  • 对治疗前骨髓样本进行细胞遗传学和荧光原位杂交检测。

主要发现

  • 发现队列良好风险与不良风险比例为82:18,验证队列为80:20。

关键数值与推荐

  • 良好风险特征:核型含+17和+18或+17或+18且无+5和+20;其余为不良风险特征。
  • 四条染色体的三体状态提供预测结局的最佳信息。

临床怎么用

  • 未来临床试验和治疗方案使用高危超二倍体作为风险分层因素时,应考虑修改定义以纳入UKALL高危超二倍体特征。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High hyperdiploidy is the most common genetic subtype of childhood acute lymphoblastic leukaemia and is associated with a good outcome. However, some patients relapse and, given its prevalence, patients with high hyperdiploidy account for a large proportion of all relapses. We aimed to evaluate putative risk factors and determine the optimal pattern of trisomies for predicting outcome. METHODS: We used discovery and validation cohorts from consecutive trials-UKALL97/99 (n=456) and UKALL2003 (n=725)-to develop the prognostic profile. UKALL97/99 recruited patients aged 1-18 years between Jan 1, 1997, and June 15, 2002, and UKALL2003 recruited children and young adults aged 1-24 years between Oct 1, 2003, and June 30, 2001, from the UK and Ireland who were newly diagnosed with acute lymphoblastic leukaemia. Cytogenetic and fluorescence in-situ hybridisation testing was performed on pre-treatment bone marrow samples by regional UK National Health Service genetic laboratories or centrally by the Leukaemia Research Cytogenetics Group, and results were reported using established nomenclature and definitions. We examined the prognostic effect of previously proposed genetic and non-genetic risk factors among patients with high hyperdiploid acute lymphoblastic leukaemia treated on UKALL2003. We used Bayesian information criterion, targeted projection pursuit, and multivariate analysis to identify the optimal number of trisomies, and best subset regression and multivariate analysis to identify the optimal combination. Survival analysis considered three endpoints, as follows: event-free survival, defined as time to relapse, second tumour, or death, censored at last contact; relapse rate, defined as time to relapse for those reaching complete remission, censored at death in remission or last contact; and overall survival, defined as time to death, censored at last contact. FINDINGS: The median follow-up time for UKALL97/99 was 10·59 years (IQR 9·25-12·06) and 9·40 years (8·00-11·55) for UKALL2003. UKALL97/99 included 208 female patients and 248 male patients, and UKALL2003 included 345 female patients and 380 male patients. We deduced that the trisomic status of four chromosomes provided the optimal information for predicting outcome. The good risk profile comprised karyotypes with +17 and +18 or +17 or +18 in the absence of +5 and +20. All remaining cases were classified in the poor risk profile. The ratio of patients with good risk and poor risk was 82:18 and 80:20 in the discovery and validation cohorts, respectively. In the validation cohort, patients with the high hyperdiploid good risk profile had an improved response to treatment compared with other patients with high hyperdiploidy at 10 years (relapse rate 5% [95% CI 3-7] vs 16% [10-23]; p<0·0001; event-free survival 92% [90-94] vs 81% [73-86]; p<0·0001; and overall survival 96% [94-97] vs 86% [79-91]; p<0·0001). The outcome for high hyperdiploid poor risk patients was similar to that of patients with an intermediate cytogenetic profile. The prognostic effect of the UKALL high hyperdiploid profile was independent of minimal residual disease and the profile outperformed other high hyperdiploid risk profiles. INTERPRETATION: Future clinical trials and treatment protocols using high hyperdiploidy as a risk stratification factor should consider modifying the definition beyond chromosome count to incorporate this novel UKALL high hyperdiploid profile. FUNDING: Blood Cancer UK.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Enshaei A, Vora A, Harrison CJ, et al. Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials. Lancet Haematol. 2021. PMID: 34715050. doi:10.1016/S2352-3026(21)00304-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。